Borrowing on the experience of end-stage chronic kidney disease [115, 116], roxadustat is now under evaluation for the treatment of anemia of lower-risk MDS with baseline EPO levels below 400 IU/L (NCT03263091). This evidence concerns the gene EPO and anemia (phenotype).